FDA Determines Regulatory Review Period for Zephyr Endobronchial Valve Implant Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Zephyr Endobronchial Valve Implant, a medical device, in accordance with US patent law, following a submission to the US Patent and Trademark Office (USPTO)